These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 3519939)

  • 41. Changes in turnover of cerebral monoamines following inhibition of enkephalin metabolism by thiorphan and bestatin.
    Llorens-Cortes C; Schwartz JC
    Eur J Pharmacol; 1984 Sep; 104(3-4):369-74. PubMed ID: 6594244
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Enkephalinase 'A' inhibition by thiorphan: central and peripheral cardiovascular effects.
    Baum T; Becker FT; Sybertz EJ; Sabin C; Desiderio DM
    Eur J Pharmacol; 1983 Oct; 94(1-2):85-91. PubMed ID: 6360696
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and pharmacological properties of 2-[S-acetylthiorphan]-1,3- diacylaminopropan-2-ol derivatives as chimeric lipid drug carriers containing an enkephalinase inhibitor.
    Lambert DM; Mergen F; Berens CF; Poupaert JH; Dumont P
    Pharm Res; 1995 Feb; 12(2):187-91. PubMed ID: 7784331
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Peptidases involved in the inactivation of exogenous and endogenous enkephalins.
    Schwartz JC; de la Baume S; Yi CC; Chaillet P; Marcais-Collado H; Costentin J
    J Neural Transm Suppl; 1983; 18():235-43. PubMed ID: 6348211
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of orally active enkephalinase inhibitors on morphine withdrawal syndrome.
    Dzoljic MR; Bokszanska A; Korenhof AM; Kaplan CD; Dzoljic M; Rupreht J; Zijlstra FJ; Brinkman EC; Cappendijk SL
    Neuroreport; 1992 Jul; 3(7):637-40. PubMed ID: 1421123
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Assessment of the abuse potential of acetorphan, an enkephalinase inhibitor.
    Knisely JS; Beardsley PM; Aceto MD; Balster RL; Harris LS
    Drug Alcohol Depend; 1989 Apr; 23(2):143-51. PubMed ID: 2702924
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Analgesic properties of enkephalinase inhibitors: animal and human studies.
    Ehrenpreis S
    Prog Clin Biol Res; 1985; 192():363-70. PubMed ID: 2934746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Potentiation of stress-induced analgesia (SIA) by thiorphan and its block by naloxone.
    Chipkin RE; Latranyi MB; Iorio LC
    Life Sci; 1982 Sep 20-27; 31(12-13):1189-92. PubMed ID: 6958954
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Changes in levels of the tripeptide Tyr-Gly-Gly as an index of enkephalin release in the spinal cord: effects of noxious stimuli and parenterally-active peptidase inhibitors.
    Llorens-Cortes C; Gros C; Schwartz JC; Clot AM; Le Bars D
    Peptides; 1989; 10(3):609-14. PubMed ID: 2780419
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endogenous opiate reward induced by an enkephalinase inhibitor, thiorphan, injected into the ventral midbrain.
    Glimcher PW; Giovino AA; Margolin DH; Hoebel BG
    Behav Neurosci; 1984 Apr; 98(2):262-8. PubMed ID: 6586195
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New carboxyalkyl inhibitors of brain enkephalinase: synthesis, biological activity, and analgesic properties.
    Fournié-Zaluski MC; Chaillet P; Soroca-Lucas E; Marçais-Collado H; Costentin J; Roques BP
    J Med Chem; 1983 Jan; 26(1):60-5. PubMed ID: 6298420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Augmented analgesic effects of enkephalinase inhibitors combined with transcranial electrostimulation.
    Malin DH; Lake JR; Hamilton RF; Skolnick MH
    Life Sci; 1989; 44(19):1371-6. PubMed ID: 2716474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Locomotor and analgesic effects of morphine and acetorphan in rats chronically treated with morphine or thiorphan.
    Khallouk-Bousselmame R; Costentin J
    Eur Neuropsychopharmacol; 1994 Jun; 4(2):137-43. PubMed ID: 7919943
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Relative involvement of mu, kappa and delta receptor mechanisms in opiate-mediated antinociception in mice.
    Ward SJ; Takemori AE
    J Pharmacol Exp Ther; 1983 Mar; 224(3):525-30. PubMed ID: 6131119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence for the involvement of opioidergic systems in medprotine-induced analgesia in the mouse.
    Caruso A; Cutuli VM; Candido P; De Bernardis E; Amico-Roxas M
    Drugs Exp Clin Res; 1994; 20(1):19-27. PubMed ID: 7924891
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The involvement of the opioidergic system in the antinociceptive mechanism of action of antidepressant compounds.
    Gray AM; Spencer PS; Sewell RD
    Br J Pharmacol; 1998 Jun; 124(4):669-74. PubMed ID: 9690858
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Role of endogenous enkephalins in locomotion and nociception studied with peptidase inhibitors in two inbred strains of mice (C57BL/6J and DBA/2J).
    Michael-Titus A; Dourmap N; Caline H; Costentin J; Schwartz JC
    Neuropharmacology; 1989 Feb; 28(2):117-22. PubMed ID: 2716968
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Labelling and exploration of the active site of enkephalinase (EC 3.4.24.11) in kidney membranes with [3H]thiorphan as ligand.
    De la Baume S; Schwartz JC
    Eur J Pharmacol; 1988 Apr; 149(1-2):121-9. PubMed ID: 3165067
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Naloxone-reversible inhibition of gall-bladder mucosal fluid secretion in experimental cholecystitis in the cat by acetorphan, an enkephalinase inhibitor.
    Jivegård L; Pollard H; Moreau J; Schwartz JC; Thune A; Svanvik J
    Clin Sci (Lond); 1989 Jul; 77(1):49-54. PubMed ID: 2758762
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characterization of enkephalin degradation in rat plasma.
    Weinberger SB; Zafuto CE; Walker RC; Martinez JL
    NIDA Res Monogr; 1986; 75():263-6. PubMed ID: 3123942
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.